<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01481649</url>
  </required_header>
  <id_info>
    <org_study_id>HKCTR-1422</org_study_id>
    <secondary_id>HKCTR-1422</secondary_id>
    <nct_id>NCT01481649</nct_id>
  </id_info>
  <brief_title>Risk of Hepatitis B Reactivation After Bone Marrow Transplantation With Prior Hepatitis B Virus (HBV) Exposure</brief_title>
  <official_title>Risk of Hepatitis B Reactivation After Hematopoietic Stem Cell Transplantation in Donors and Recipients With Prior HBV Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether preemptive nucleoside analogue therapy or&#xD;
      regular virologic monitoring is the preferred method in management patients with prior&#xD;
      exposure to hepatitis B vius (HBV) and undergoing hematopoietic stem cell transplantation&#xD;
      (HSCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Occult hepatitis B virus (HBV) reactivation has been documented in bone marrow&#xD;
      transplantation recipients who are hepatitis B surface antigen (HBsAg)-negative but with&#xD;
      serologic evidence of prior exposure to HBV. However detailed prospective studies documenting&#xD;
      the incidence of reactivation and the virologic and serologic kinetics of reactivation are&#xD;
      lacking. The investigators prospective study proposes to follow-up 50 such bone marrow&#xD;
      transplant recipients with all serologic and virologic parameters monitored every 4 weeks.&#xD;
      Patients with detectable HBV DNA will be started on nucleoside analogue therapy. The optimal&#xD;
      method and duration of monitoring will also be determined from our study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HBV reactivation (defined as detectable HBV DNA &gt;20 IU/mL)</measure>
    <time_frame>2 years</time_frame>
    <description>From date of hematopoietic stem cell transplantation (HSCT) to 2 years after HSCT.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">69</enrollment>
  <condition>Exposure to Hepatitis B Virus</condition>
  <arm_group>
    <arm_group_label>HBsAg-negative, anti-HBc-positive</arm_group_label>
    <description>HBsAg-negative, anti-HBc-positive subjects undergoing hematopoietic stem cell transplantation (HSCT)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma for hepatitis B virus genotypic, virologic and serologic testing&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred for hematopoietic stem cell transplantation (HSCT) in Hong Kong&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented HBsAg-negative HSCT recipient with or without antibody to the hepatitis B&#xD;
             surface antigen (anti-HBs).&#xD;
&#xD;
          -  Documented anti-HBc (total)-positive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant liver diseases including chronic hepatitis C and D infection, Wilson's&#xD;
             disease, autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing&#xD;
             cholangitis.&#xD;
&#xD;
          -  Significant alcohol intake (&gt;30 grams per day)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wai-Kay Seto, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, The University of Hong Kong, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>November 24, 2011</study_first_submitted>
  <study_first_submitted_qc>November 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis B</keyword>
  <keyword>anti-HBc</keyword>
  <keyword>HBsAg</keyword>
  <keyword>HSCT</keyword>
  <keyword>recipients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

